Bayer (BAYN) Given “Buy” Rating at Citigroup
Bayer (FRA:BAYN)‘s stock had its “buy” rating reiterated by equities researchers at Citigroup in a research report issued to clients and investors on Wednesday.
A number of other equities research analysts also recently weighed in on BAYN. Sanford C. Bernstein set a €129.00 ($153.57) price target on Bayer and gave the stock a “buy” rating in a research note on Wednesday. Warburg Research set a €121.00 ($144.05) price target on Bayer and gave the stock a “neutral” rating in a research note on Thursday, January 11th. Independent Research set a €120.00 ($142.86) price target on Bayer and gave the stock a “neutral” rating in a research note on Friday, January 12th. Jefferies Group set a €125.00 ($148.81) price target on Bayer and gave the stock a “buy” rating in a research note on Tuesday. Finally, JPMorgan Chase & Co. set a €128.00 ($152.38) price target on Bayer and gave the stock a “buy” rating in a research note on Wednesday, January 10th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. Bayer has a consensus rating of “Buy” and an average price target of €121.67 ($144.84).
Shares of Bayer (FRA BAYN) opened at €103.48 ($123.19) on Wednesday. Bayer has a one year low of €99.69 ($118.68) and a one year high of €123.82 ($147.40). The firm has a market capitalization of $85,870.00 and a PE ratio of 27.74.
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.